Home›Trial›NCT05808634
NCT05808634Phase 1RECRUITING

Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

Study Summary

The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma

Conditions
Advanced Adenocarcinoma
Interventions / Drugs
BA3182
View on ClinicalTrials.gov ↗
Sponsor
BCAB
BioAtla Inc
Oncology
D48/100
Study Details
Enrollment168 participants
Primary Completion—
Lead SponsorBioAtla, Inc.
Data Retrieved2026-04-11 04:07:01.755208+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 168 participants
Sponsor Catalyst Profile

BioAtla Inc (BCAB) is the sponsoring company for this trial. BiotechSign currently grades this company D (48/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

BCAB Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.